Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.

Minesapride was safe and well-tolerated. Although the primary endpoint was negative, minesapride 40 mg is likely to improve the stricter composite endpoint and SBM frequency. Japan Pharmaceutical Information Center Number: Japic CTI-163459.